Skip to content Skip to footer
Site Search

Menu

Industries

Menu

Aerospace, defence & security

Menu

Capital projects & infrastructure

Menu

Energy, utilities & resources

Menu

Engineering & construction

Menu

Forest, paper & packaging

Menu

Government & public services

Menu

Hospitality & leisure

Menu

Pharmaceuticals & life sciences

Menu

Technology, media & Telecommunications

Menu

Transportation & logistics

Featured

Global Consumer Insights Pulse Survey - June 2022

Achieving net zero infrastructure

Manufacturing COO Pulse Survey

Menu

Services

Featured

Ukraine: Tax, Legal and People considerations

Digital Trust Insights Survey 2022

M&A industry trends report

Loading Results

Pharma 2020: from vision to decision

About the Pharma 2020 series

The Pharmaceutical industry's long successful strategy of placing big bets on a few molecules, promoting them heavily and turning them into blockbusters worked well for many years, but its R&D productivity has now plummeted and the environment’s changing. PwC believes that seven major trends are reshaping the marketplace:

  • Instances of chronic disease are increasing, placing even greater pressure on already stretched healthcare budgets
  • Healthcare policy-makers and payers are increasingly mandating what doctors can prescribe
  • A growing number of healthcare payers are measuring the pharmacoeconomic performance of different medicines. A widespread use of electronic medical records will give them the data they need to insist on outcomes-based pricing
  • Boundaries between different forms of healthcare are blurring, as clinical advances render previously fatal diseases chronic and the self-medication sector expands
  • Demand for medicines is growing more rapidly in the emerging economies than the industrialized economies
  • Governments are beginning to focus on prevention rather than treatment, although they have not yet invested very much in pre-emptive measures; and
  • Regulators are becoming more cautious about approving truly innovative medicines.

These trends will compound the challenges Pharma already faces, but they’ll also provide some major opportunities.

"It was the best of the times, it was the worst of times..."

{{filterContent.facetedTitle}}

{{contentList.dataService.numberHits}} {{contentList.dataService.numberHits == 1 ? 'result' : 'results'}}
{{contentList.loadingText}}
{{contentList.loadingText}}
{{contentList.loadMoreLabel}} {{contentList.viewAllLabel}}

Download Pharma 2020: From vision to decision

We look at how pharma companies can reach 2020 in a position to benefit from more favourable conditions thereafter - and the most important decisions senior managers will need to make.
Or view other language and related documents

Further languages:

Contact us

Ron Chopoorian

Ron Chopoorian

Global Health Industries Leader, Partner, PwC United States

Email
Peter Kartscher

Peter Kartscher

Global Pharmaceutical and Life Sciences Assurance Leader, PwC Switzerland

Tel: +41 79 5429018

Email
Andrew Packman

Andrew Packman

Global Pharmaceutical and Life Sciences Tax Leader, PwC United Kingdom

Tel: +44 (0)771 266 64 41

Email
Hide
PwC office locations Site map Contact us

© 2017 - 2022 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please see www.pwc.com/structure for further details.